Arie is Chairman of Bellco Capital, a Los Angeles-based investment firm that focuses on deploying capital to create and support transformative companies in life science, real estate, agtech, and other sectors. Arie is also Executive Chairman and Co-Founder of Allogene, a clinical-stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Arie founded and was Chairman, President & CEO of Kite Pharma, acquired in 2017 by Gilead just prior to approval of Yescarta® as the first CAR T therapy for non-Hodgkin lymphoma. He currently serves as Chairman of Two River Group, UroGen Pharma, and Kronos Bio and as co-Chair of Breakthrough Properties LLC. He serves as director of IconOVir Bio, Inc., ByHeart, and Gingko Bioworks and is also Co-Founder and Senior Managing Director of Vida Ventures, a life science venture group. Arie is Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Founder and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, Arie was at the NCI/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his MD at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School.